• Profile
Close

Efficacy and safety of tumor necrosis factor antagonists in treatment of internal fistulizing Crohn disease

Clinical Gastroenterology and Hepatology Jan 16, 2020

Bouguen G, Huguet A, Amiot A, et al. - Researchers conducted a retrospective study of data collected from the Groupe d’Etude Thérapeutique des Affections Inflammatoires Digestives trial, from January 1, 2000, through December 31, 2017, in order to evaluate the long-term effectiveness and safety of anti-TNF therapy for people with internal fistulas. A total of 68 people who underwent major abdominal surgery, after a median follow-up period of 3.5 years. A concentration of C-reactive protein >18 mg/L, and albumin concentration <36 g/L, the appearance of an abscess at the fistula diagnosis, the association among the appearance of a stricture independently with the necessity for surgery. Overall, from a large clinical trial, a retrospective analysis of data was observed that anti-TNF therapy delays or prevents surgery for almost half of people with CD and luminal fistulas. Perhaps the risk of sepsis-related death or gastrointestinal malignancies were increased by anti-TNF therapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay